KR840006765A - 지속성 방출 고형 제형의 제조방법 - Google Patents
지속성 방출 고형 제형의 제조방법 Download PDFInfo
- Publication number
- KR840006765A KR840006765A KR1019830005160A KR830005160A KR840006765A KR 840006765 A KR840006765 A KR 840006765A KR 1019830005160 A KR1019830005160 A KR 1019830005160A KR 830005160 A KR830005160 A KR 830005160A KR 840006765 A KR840006765 A KR 840006765A
- Authority
- KR
- South Korea
- Prior art keywords
- tablet
- sustained
- release
- layer
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (18)
- 핵정에 하나 이상의 지속성 방출 외층을 코팅시킴으로서 약제를 실질적으로 0차 방출시키는 정제를 제조하는 방법에 있어서, 핵정 및 하나이상의 지속성-방출 외층은 약제, 친수성 겔 및 부형제의 혼합물로 주로 이루어지며, 친수성 겔의 농도는 핵정 및 각각의 지속성-방출 외층에서 거의 일정하며 핵정 또는 특정한 지속성-방출 층의 약제량은 다음식에 의해 결정됨을 특징으로 하는 방법.여기에서, DL은 핵정 또는 특정한 지속성-방출층중의 약제량이며, DT는 정제의 지속성-방출 부위중 약제의 총 양이고, RD는 필요한 약제량을 구하고자 하는 핵정 또는 외층의 미분반경이며, RT는 정제의지속성-방출 부위의 반경이다.
- 제1항에 있어서, 정제가, 1개의 외층을 갖는 방법.
- 제2항에 있어서, 친수성 겔이 하이드록시프로필메틸셀룰로스인 방법.
- 제3항에 있어서, 하이드록시프로필메틸셀룰로스의 점도가 4000센티포아스인 방법.
- 제2항에 있어서, 약제가 터부탈린인 방법.
- 제2항에 있어서, 약제가 터페나딘인 방법.
- 제2항에 있어서, 약제가 슈도에페드린 HCI인 방법.
- 제2항에 있어서, 정제가 외부 비-지속성, 방출층을 갖는 방법.
- 제8항에 있어서, 외부, 비-지속성, 방출층의 약제가 터페나딘이며 핵정 및 지속성-방출, 외층의 약제가 슈도에페드린 HCI인 방법.
- 제1항에 있어서, 정제가 2내지 4개의 외층을 갖는 방법.
- 제10항에 있어서, 친수성 겔이 하이드록시프로필 메틸셀룰로스인 방법.
- 제11항에 있어서, 하이드록시프로필메틸렐룰로스의 점도가 4000센티포아스인 방법.
- 제10항에 있어서, 약제가 터부탈린인 방법.
- 제10항에 있어서, 약제가 터페나딘인 방법.
- 제10항에 있어서, 약제가 슈도에페드린 HCI인 방법.
- 제1항에 있어서, 정제가 2개의 지속성-방출, 외층을 갖는 방법.
- 제16항에 있어서, 정제가 외부 비-지속성, 방출 층을 갖는 방법.
- 제17항에 있어서, 외부의 비-지속성, 방출층의 약제는 터페나딘이며 지속성-방출층 및 핵정의 약제는 슈도에페드린 HCI인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43810082A | 1982-11-01 | 1982-11-01 | |
US438100 | 1982-11-01 | ||
US438,100 | 1982-11-01 | ||
US53612883A | 1983-09-27 | 1983-09-27 | |
US536,128 | 1983-09-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR840006765A true KR840006765A (ko) | 1984-12-03 |
KR900007311B1 KR900007311B1 (ko) | 1990-10-08 |
Family
ID=27031546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019830005160A KR900007311B1 (ko) | 1982-11-01 | 1983-10-31 | 지속성 방출 고형 제형의 제조방법 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0111144B1 (ko) |
KR (1) | KR900007311B1 (ko) |
AU (1) | AU554377B2 (ko) |
CA (1) | CA1220137A (ko) |
DE (1) | DE3368011D1 (ko) |
DK (1) | DK499183A (ko) |
ES (1) | ES8607008A1 (ko) |
GR (1) | GR78740B (ko) |
IE (1) | IE56182B1 (ko) |
IL (1) | IL70071A (ko) |
NO (1) | NO163356C (ko) |
NZ (1) | NZ206094A (ko) |
PH (1) | PH20332A (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE33994E (en) * | 1983-08-16 | 1992-07-14 | Burroughs Wellcome Co. | Pharmaceutical delivery system |
US4624848A (en) * | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4749576A (en) * | 1984-05-10 | 1988-06-07 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
DE3486409T2 (de) * | 1984-08-17 | 1996-04-25 | Wellcome Found | Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs. |
US5219575A (en) * | 1987-06-26 | 1993-06-15 | Duphar International Research B.V. | Compositions with controlled zero-order delivery rate and method of preparing these compositions |
EP0297650A1 (en) * | 1987-06-26 | 1989-01-04 | Duphar International Research B.V | Compositions with controlled zero-order delivery rate and method of preparing these compositions |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
CN1053570C (zh) * | 1987-10-07 | 2000-06-21 | 默尔多药物公司 | 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法 |
US4999226A (en) * | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
US5198227A (en) * | 1990-01-22 | 1993-03-30 | Mcneil-Ppc, Inc. | Dual subcoated simulated capsule medicament |
DK0707475T3 (da) * | 1993-06-14 | 1997-12-29 | Janssen Pharmaceutica Nv | Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin |
US5484607A (en) * | 1993-10-13 | 1996-01-16 | Horacek; H. Joseph | Extended release clonidine formulation |
US5451409A (en) * | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
US5393765A (en) * | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
DE19608423A1 (de) * | 1996-03-05 | 1997-09-11 | Merck Patent Gmbh | Implantate mit phasenweiser Arzneistoffabgabe |
US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
DE10031043A1 (de) | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
KR100402053B1 (ko) * | 2000-09-28 | 2003-10-17 | 한국화학연구원 | 항생제의 서방성 임플란트 제제 |
ES2663873T3 (es) * | 2001-10-29 | 2018-04-17 | Massachusetts Institute Of Technology | Forma farmacéutica con perfil de liberación de orden cero fabricada por impresión tridimensional |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
CA2689978A1 (en) | 2007-06-08 | 2008-12-18 | Addrenex Pharmaceuticals, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
CN103370058A (zh) | 2010-12-22 | 2013-10-23 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
CA2978680A1 (en) | 2015-03-04 | 2016-09-09 | Arnold Forbes | Compositions and methods for treating drug addiction |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1139869A (en) * | 1966-01-06 | 1969-01-15 | Moore Medicinal Products Ltd | Improvements in or relating to tablets |
US3965255A (en) * | 1974-05-01 | 1976-06-22 | E. E. Eljim Ecology Ltd. | Controlled drug releasing preparations |
SE418247B (sv) * | 1975-11-17 | 1981-05-18 | Haessle Ab | Sett att framstella kroppar med reglerad frigoring av en aktiv komponent |
US4122157A (en) * | 1977-03-04 | 1978-10-24 | Richardson-Merrell Inc. | Nitrofurantoin sustained release tablet |
GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
-
1983
- 1983-10-27 IL IL70071A patent/IL70071A/xx unknown
- 1983-10-28 PH PH29776A patent/PH20332A/en unknown
- 1983-10-28 AU AU20803/83A patent/AU554377B2/en not_active Ceased
- 1983-10-28 ES ES526901A patent/ES8607008A1/es not_active Expired
- 1983-10-28 NZ NZ206094A patent/NZ206094A/en unknown
- 1983-10-28 IE IE2543/83A patent/IE56182B1/en not_active IP Right Cessation
- 1983-10-31 DE DE8383110874T patent/DE3368011D1/de not_active Expired
- 1983-10-31 EP EP83110874A patent/EP0111144B1/en not_active Expired
- 1983-10-31 CA CA000440061A patent/CA1220137A/en not_active Expired
- 1983-10-31 DK DK499183A patent/DK499183A/da not_active Application Discontinuation
- 1983-10-31 KR KR1019830005160A patent/KR900007311B1/ko not_active IP Right Cessation
- 1983-10-31 GR GR72829A patent/GR78740B/el unknown
- 1983-10-31 NO NO833961A patent/NO163356C/no unknown
Also Published As
Publication number | Publication date |
---|---|
GR78740B (ko) | 1984-10-02 |
NZ206094A (en) | 1986-10-08 |
ES8607008A1 (es) | 1986-06-16 |
CA1220137A (en) | 1987-04-07 |
PH20332A (en) | 1986-12-02 |
NO163356C (no) | 1990-05-16 |
DE3368011D1 (en) | 1987-01-15 |
DK499183D0 (da) | 1983-10-31 |
IL70071A (en) | 1987-12-31 |
AU2080383A (en) | 1984-05-10 |
DK499183A (da) | 1984-05-02 |
NO833961L (no) | 1984-05-02 |
AU554377B2 (en) | 1986-08-21 |
NO163356B (no) | 1990-02-05 |
ES526901A0 (es) | 1986-06-16 |
EP0111144A1 (en) | 1984-06-20 |
EP0111144B1 (en) | 1986-12-03 |
IE832543L (en) | 1984-05-01 |
IL70071A0 (en) | 1984-01-31 |
IE56182B1 (en) | 1991-05-08 |
KR900007311B1 (ko) | 1990-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840006765A (ko) | 지속성 방출 고형 제형의 제조방법 | |
KR870700344A (ko) | 유효 화합물을 서서히 방출하는 신규 약제, 그의 제조방법 및 이신규 제제물의 용도 | |
ATE9695T1 (de) | Antihistamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
DE3676626D1 (de) | Verfahren zur herstellung einer darreichungs- und dosierungsform fuer arzneimittel-wirkstoffe, reagentien oder andere wirkstoffe. | |
KR860000068A (ko) | 약제에의 지효성 제공방법 | |
KR860000800A (ko) | 용해 유체내의 유효성분을 영차 방출하는 시방정 및 이의 제조방법 | |
NO20073429L (no) | Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat | |
AR029605A1 (es) | DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS | |
DE69104991D1 (de) | Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen. | |
FR2511357B1 (fr) | Cis-platine microcristallin, son procede de preparation et composition pharmaceutique le contenant | |
ATE20518T1 (de) | Trockene pulverige allergenzusammensetzung und verfahren zu deren herstellung. | |
ATE444737T1 (de) | Pharmakologisch aktive ionisierbare substanzen enthaltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung | |
KR950701214A (ko) | 눈에 투여를 위한 약제학적 투약 형태 및 그 제조방법(galenic form for ocular administraion and process for the preparation of same) | |
DE2967701D1 (de) | A-21978 genannte antibiotische mischung, verfahren zu ihrer herstellung, ihre pharmazeutischen zusammensetzungen und produzierender mikroorganismus. | |
ES2016620B3 (es) | Sistema para liberar medicamentos con bioaceptabilidad mejorada. | |
AT363936B (de) | Verfahren zur herstellung von neuen cyproheptadinderivaten und von deren pharmazeutisch verwendbaren salzen sowie optischen isomeren | |
NL169076B (nl) | Werkwijze voor het bereiden of vervaardigen van farmacologische preparaten met een analgetische en antipyretische werking, alsmede werkwijze voor het bereiden van geneeskrachtige verbindingen, welke geschikt zijn voor gebruik in dergelijke preparaten. | |
DE3777122D1 (de) | Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE1734T1 (de) | Schmerzstillende tablette und verfahren zu deren herstellung. | |
DE3681334D1 (de) | Androstane-17-beta-carbonsaeureester, verfahren zu deren herstellung und pharmazeutische praeparate die diese enthalten. | |
Rojanasthien et al. | Bioequivalence study of modified‐release gliclazide tablets in healthy volunteers | |
NL170283C (nl) | Werkwijze voor het bereiden van verbindingen met een analgetische en ontstekingsremmende activiteit, alsmede daarmede vervaardigde, gevormde geneesmiddelen. | |
AR013352A1 (es) | Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica. | |
BRPI0307319B8 (pt) | forma de dosagem oral para liberação controlada de droga e processo para sua preparação | |
FR2391202A1 (fr) | Triazines-1,2,4 substituees, actives pharmacologiquement et medicaments contenant ces triazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |